X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (785) 785
Book Review (90) 90
Newsletter (23) 23
Newspaper Article (22) 22
Publication (22) 22
Book Chapter (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (672) 672
humans (607) 607
female (388) 388
male (388) 388
glycopyrrolate (368) 368
glycopyrrolate - administration & dosage (336) 336
adult (248) 248
middle aged (231) 231
glycopyrrolate - pharmacology (193) 193
glycopyrrolate - therapeutic use (178) 178
aged (158) 158
double-blind method (157) 157
muscarinic antagonists - administration & dosage (152) 152
pulmonary disease, chronic obstructive - drug therapy (146) 146
glycopyrrolate - adverse effects (145) 145
heart rate - drug effects (137) 137
treatment outcome (137) 137
animals (118) 118
anesthesiology (117) 117
abridged index medicus (114) 114
respiratory system (113) 113
administration, inhalation (105) 105
lung diseases, obstructive (104) 104
muscarinic antagonists - therapeutic use (101) 101
obstructive pulmonary-disease (100) 100
atropine (99) 99
copd (98) 98
time factors (94) 94
pharmacology & pharmacy (93) 93
bronchodilator agents - administration & dosage (92) 92
tiotropium (88) 88
anesthesia (82) 82
muscarinic antagonists - adverse effects (82) 82
adolescent (81) 81
chronic obstructive pulmonary disease (77) 77
drug therapy (77) 77
pulmonary disease, chronic obstructive - physiopathology (77) 77
dose-response relationship, drug (75) 75
drug combinations (74) 74
blood pressure - drug effects (73) 73
glycopyrronium (73) 73
efficacy (72) 72
atropine - administration & dosage (70) 70
cross-over studies (69) 69
dosage and administration (69) 69
child (68) 68
safety (68) 68
atropine - pharmacology (65) 65
care and treatment (65) 65
double-blind (65) 65
muscarinic antagonists - pharmacology (62) 62
research (61) 61
drug therapy, combination (60) 60
indans - administration & dosage (59) 59
quinolones - administration & dosage (59) 59
bronchodilator agents - adverse effects (58) 58
surgery (54) 54
indacaterol (52) 52
severity of illness index (52) 52
veterinary sciences (50) 50
pulmonary disease, chronic obstructive - diagnosis (49) 49
pyrrolidines - pharmacology (49) 49
children (48) 48
analysis (46) 46
bronchodilator agents - therapeutic use (46) 46
pediatrics (46) 46
preanesthetic medication (45) 45
drug administration schedule (44) 44
glycopyrrolate - pharmacokinetics (44) 44
injections, intravenous (44) 44
neostigmine (44) 44
child, preschool (43) 43
management (43) 43
prospective studies (43) 43
clinical trials (42) 42
pharmacokinetics (42) 42
adrenergic beta-2 receptor agonists - administration & dosage (40) 40
forced expiratory volume (40) 40
formoterol (40) 40
premedication (40) 40
aged, 80 and over (39) 39
health aspects (39) 39
administration, oral (38) 38
dermatology (37) 37
lung - physiopathology (37) 37
drugs (36) 36
lung - drug effects (36) 36
young adult (36) 36
diseases of the respiratory system (35) 35
hyperhidrosis - drug therapy (35) 35
infant (35) 35
hyperhidrosis (34) 34
patients (34) 34
neostigmine - pharmacology (33) 33
pharmaceutical industry (33) 33
administration, topical (32) 32
dogs (32) 32
drug dosages (32) 32
forced expiratory volume - drug effects (32) 32
indans - adverse effects (32) 32
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (806) 806
German (10) 10
Danish (3) 3
Japanese (3) 3
Korean (3) 3
Spanish (3) 3
French (2) 2
Czech (1) 1
Hungarian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents | Index Medicus
Journal Article
European Respiratory Journal, ISSN 0903-1936, 12/2013, Volume 42, Issue 6, pp. 1484 - 1494
Journal Article
Thorax, ISSN 0040-6376, 04/2015, Volume 70, Issue 4, pp. 311 - 319
Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the... 
INDACATEROL | THERAPY | RESPIRATORY SYSTEM | DAILY SALMETEROL | DUAL BRONCHODILATION | LUNG-FUNCTION | DOUBLE-BLIND | EXACERBATIONS | OUTCOMES | GLYCOPYRRONIUM | HEALTH-STATUS | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Ethanolamines - administration & dosage | Indans - therapeutic use | Vital Capacity - drug effects | Quinolones - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Scopolamine Derivatives - administration & dosage | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Ethanolamines - therapeutic use | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Analysis | Formoterol | Indacaterol | Dosage and administration | Diagnosis | Quality of life | Index Medicus | 1506 | Chronic Obstructive Pulmonary Disease | COPD Pharmacology
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 199 - 209
Summary Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on exacerbations in patients with severe and very severe... 
Pulmonary/Respiratory | INDACATEROL | PROPIONATE | THERAPY | EFFICACY | RESPIRATORY SYSTEM | LUNG-FUNCTION | PREVENTION | OUTCOMES | HEALTH-STATUS | COPD | SALMETEROL | CRITICAL CARE MEDICINE | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Dose-Response Relationship, Drug | Quinolones - adverse effects | Scopolamine Derivatives - administration & dosage | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Respiratory Function Tests - methods | Administration, Inhalation | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Disease Progression | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Respiratory System - drug effects | Respiratory System - physiopathology | Aged | Drug Monitoring | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus | Clinical Medicine | Lungmedicin och allergi | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Respiratory Medicine and Allergy
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2017, Volume 126, pp. 105 - 115
Abstract Background The long-term safety and efficacy of a novel Co-Suspension™ Delivery Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg... 
Pulmonary/Respiratory | Muscarinic antagonists | Co-Suspension™ Delivery Technology | Metered dose inhaler | β2-agonist | COPD | β | agonist | INDACATEROL | TWICE-DAILY FORMOTEROL | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | QVA149 | COMBINATION | ONCE-DAILY TIOTROPIUM | Co-Suspension (TM) Delivery Technology | THERAPY | RESPIRATORY SYSTEM | GLYCOPYRRONIUM | beta-agonist | COPD PATIENTS | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Muscarinic Antagonists - therapeutic use | Tiotropium Bromide - administration & dosage | Metered Dose Inhalers - utilization | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Drug Therapy, Combination | Glycopyrrolate - adverse effects | Severity of Illness Index | Formoterol Fumarate - pharmacology | Drug Tolerance | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Tiotropium Bromide - pharmacology | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Smoking - epidemiology | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Glycopyrrolate - pharmacology | Aged | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Medical colleges | Formoterol | Lung diseases, Obstructive | Care and treatment | Respiratory therapy | Drugs | Drug delivery systems | Effectiveness | Statistical analysis | Lung diseases | Clinical trials | Glycopyrrolate | Long term | Side effects | Randomization | Dyspnea | Technology | Obstructive lung disease | Chronic obstructive pulmonary disease | Safety | Drug therapy | Respiration | Index Medicus
Journal Article
International Journal of COPD, ISSN 1176-9106, 05/2017, Volume 12, pp. 1325 - 1337
Background: Endpoints that evaluate deterioration rather than improvement of disease may have clinical utility in COPD. In this analysis, we compared the... 
IND/GLY | Deterioration | COPD | LUNG-FUNCTION | QVA149 | SALMETEROL-FLUTICASONE | OBSTRUCTIVE PULMONARY-DISEASE | deterioration | UMECLIDINIUM/VILANTEROL | RESPIRATORY SYSTEM | PARALLEL-GROUP | DOUBLE-BLIND | EXACERBATIONS | GLYCOPYRRONIUM | HEALTH-STATUS | Indans - adverse effects | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Clinical Trials, Phase III as Topic | Quinolones - adverse effects | Tiotropium Bromide - administration & dosage | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Endpoint Determination | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Tiotropium Bromide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Lung - physiopathology | Disease Progression | Fluticasone-Salmeterol Drug Combination - administration & dosage | Randomized Controlled Trials as Topic | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Tiotropium | Lung diseases, Obstructive | Indacaterol | Dosage and administration | Glycopyrrolate | Research | Drug therapy | Index Medicus
Journal Article
International Journal of COPD, ISSN 1176-9106, 02/2014, Volume 9, pp. 215 - 228
Background: Addition of a second bronchodilator from a different pharmacological class may benefit patients with moderate-to-severe chronic obstructive... 
Bronchodilation | Indacaterol | Inhalation therapy | Breezhaler | Glycopyrronium | COPD | inhalation therapy | PLACEBO | DAILY NVA237 | COMBINATION | TRIAL | FORMOTEROL | BETA-AGONIST | OBSTRUCTIVE PULMONARY-DISEASE | Breezhaler (R) | indacaterol | IPRATROPIUM | RESPIRATORY SYSTEM | glycopyrronium | TIOTROPIUM | bronchodilation | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Area Under Curve | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Female | Indans - administration & dosage | Inspiratory Capacity | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Drug Administration Schedule | Europe | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Muscarinic Antagonists - administration & dosage | Vital Capacity | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Dosage and administration | Glycopyrrolate | Drug therapy, Combination | Drug therapy | Comparative analysis | Index Medicus
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 04/2018, Volume 49, pp. 20 - 26
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2016, Volume 120, pp. 16 - 24
Abstract Background This study formed part of the dose selection for a glycopyrrolate (GP)/formoterol fumarate (FF) fixed-dose combination formulated using... 
Pulmonary/Respiratory | Bronchodilators | Co-Suspension™ Delivery Technology | Fixed-dose combinations | LAMA | COPD maintenance therapy | LABA | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | SAFETY | HYPERINFLATION | VALIDATION | Co-Suspension (TM) Delivery Technology | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | OUTCOMES | GLYCOPYRRONIUM | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Tiotropium Bromide - administration & dosage | Metered Dose Inhalers - utilization | Female | Dry Powder Inhalers - methods | Glycopyrrolate - adverse effects | Double-Blind Method | Formoterol Fumarate - pharmacology | Tiotropium Bromide - adverse effects | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Tiotropium Bromide - pharmacology | Cholinergic Antagonists - administration & dosage | Cross-Over Studies | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Adrenergic beta-2 Receptor Agonists - administration & dosage | Glycopyrrolate - pharmacology | Drug Combinations | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Clinical trials | Formoterol | Dosage and administration | Drug therapy, Combination | Comparative analysis | Complications and side effects | Respiratory agents | Respiratory therapy | Electrocardiography | Chronic obstructive pulmonary disease | Effectiveness | Pharmaceutical industry | Index Medicus
Journal Article
13.